<DOC>
	<DOCNO>NCT02693821</DOCNO>
	<brief_summary>The study 's objective evaluate gabapentine efficiency orally long term use painfully surgery .</brief_summary>
	<brief_title>Persistent Postoperative Pain</brief_title>
	<detailed_description>This study : control , prospective , randomize double blind . Its main objective evaluate pre postoperative Gabapentin efficiency orally dose long term use order prevent decrease persistent postoperative pain ( PPP ) surgeries high incidence ( Pain ) . Patients randomly divide two branch ; one take 600 mg Gabapentin twice day group take Placebo ( twice day also ) . Both group patient take one pill day surgery ( 300 mg ) pill surgery day ( 300mg ) . After , patient continue treatment 30 day ( two dos per day Gabapentin placebo ) . After surgery take second pill , evaluate : postoperative sharp pain , sickness , vomit , sedation adverse effect . Patients evaluate pain treatment office ( consult room ) follow time : 1 . 30 day surgery . ( take drug suspend ) 2 . 3 month surgery . 3 . 6 month surgery . 4 . 12 month surgery This monitoring treatment do order evaluate presence absence persistent postoperative pain ( PPP ) .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients require persistent painfully surgery breast surgery ( mastectomy breast implant ) , herniorrhaphies ( laparoscopical ) unilateral bilateral , amputation upper low limbs chest surgery ( thoracotomy , thoracoscopy , sternotomies ) . Patients already sign inform consent . Patients age 21 75 . ASA I II _ III ( Classification system American Society Anesthesiologists ( ASA ) use estimate anesthesiology risk patient may suffer ) BMI , 35 Kg/m2 . Pregnant woman Patients suffer liver renal failure ( plasma creatinine 1.5 mg/ml creatinine clearance le 60 ml/min ) , heart failure neurological dysfunction . Diabetic patient Gabapentine allergic patient</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gabapentin</keyword>
	<keyword>prevention</keyword>
	<keyword>incidence</keyword>
</DOC>